Plain-English translation of NCT06295614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a treatment called ARC-IM Therapy, which uses an implanted device that sends electrical stimulation to your spinal cord to help improve walking and balance problems caused by Parkinson's disease. The therapy builds on earlier research that showed promising results in reducing these movement difficulties. Researchers want to see if this new version of the device is safe and effective, and whether it can be used safely at home.
Many people with advanced Parkinson's disease develop severe walking problems—like difficulty with balance or sudden freezing—that don't respond well to current medications. This new treatment aims to fill that gap by offering a different approach to help restore movement and independence.
You likely qualify if…
You likely don't qualify if…
During your first year, you will have baseline assessments, undergo surgery to implant the stimulation device, attend sessions to configure and optimize the device settings, and participate in rehabilitation both at the clinic and at home. After the first year, you will continue using the device at home for 3 additional years while the research team monitors your safety and health through regular follow-up visits. The total time commitment is 4 years, with the most intensive participation during the first year.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Switzerland